EUCTR2011-003618-18-BE进行中（未招募）不适用
A Randomized, Double-Blind, Phase 2, Dose-RangingStudy to Evaluate the Safety and Efficacy ofVeliparib and Whole Brain Radiation Therapy VersusPlacebo and Whole Brain Radiation Therapy inSubjects with Brain Metastases from Non-Small CellLung Cancer
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 330
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subject must be = 18 years of age;
- •Subject must have cytologically or histologically confirmed NSCLC;
- •Subject must have brain metastases as demonstrated on a MRI brain scan;
- •Subject must be eligible for WBRT;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 80
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 250
排除标准
- •Subject was diagnosed with brain metastasis >28 days prior to Treatment Day 1;
- •Subject received any prior form of cranial radiation and/or neurosurgery for brain metastasis;
- •Subject has a Karnofsky Performance Score (KPS) of < 70;
- •Subject has significant dyspnea requiring supplemental oxygen therapy;
- •Subject has liver metastases (restaging is not required for known liver metastasis);
- •Subject has more than 2 sites (organ systems) of metastases from NSCLC with the exception of the following: intra-cranial sites of metastasis from NSCLC, thoracic sites of metastasis from NSCLC, and bone metastasis;
- •Subject has leptomeningeal metastases or subarachnoid spread of tumor as demonstrated on a baseline MRI brain scan;
- •Subject's last dose of chemotherapy or investigational therapy was = 7 days prior to Treatment Day 1;
- •Subject has unresolved or unstable, serious toxicity from prior administration of another investigational drug and/or prior anti-cancer treatment;
- •Subject has a known seizure disorder that is uncontrolled, or has seizures occurring greater than or equal to 3 times a week over the past month. Subjects presenting with symptoms of seizures from the brain metastasis are eligible however he/she should receive adequate anti-seizure medication prior to study treatment;
- •Subject is pregnant or lactating;
- •Subject has previously been treated with a PARP inhibitor as an investigational agent;
- •Subject has clinically significant and uncontrolled major medical condition(s)
研究者
相似试验
进行中（未招募）
不适用
A Study of Whole Brain Radiation Therapy (WBRT) with Veliparib or without Veliparib in patients with Brain Metastases from Non-Small Cell Lung Cancer.Brain metastases from NSCLCMedDRA version: 17.1Level: LLTClassification code 10006128Term: Brain metastasesSystem Organ Class: 100000004864EUCTR2011-003618-18-FIAbbVie Deutschland GmbH & Co. KG330
进行中（未招募）
不适用
A Study of Whole Brain Radiation Therapy (WBRT) with Veliparib or without Veliparib in patients with Brain Metastases from Non-Small Cell Lung Cancer.EUCTR2011-003618-18-HUAbbVie Deutschland GmbH & Co. KG300
进行中（未招募）
不适用
A Study of Whole Brain Radiation Therapy (WBRT) with Veliparib or without Veliparib in patients with Brain Metastases from Non-Small Cell Lung Cancer.Brain metastases from NSCLCMedDRA version: 14.1Level: LLTClassification code 10006128Term: Brain metastasesSystem Organ Class: 100000004864EUCTR2011-003618-18-CZAbbVie Deutschland GmbH & Co. KG330
进行中（未招募）
不适用
A Study of Whole Brain Radiation Therapy (WBRT) with Veliparib or without Veliparib in patients with Brain Metastases from Non-Small Cell Lung Cancer.EUCTR2011-003618-18-ESAbbVie Deutschland GmbH & Co. KG330
进行中（未招募）
1 期
A Study of Whole Brain Radiation Therapy (WBRT) with Veliparib or without Veliparib in patients with Brain Metastases from Non-Small Cell Lung Cancer.Brain metastases from NSCLCMedDRA version: 14.1 Level: LLT Classification code 10006128 Term: Brain metastases System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003618-18-NOAbbott GmbH & Co. KG307